RxDoctor Payments Data

Naushaba Khalid, MD

Nephrology · Royal Oak, MINPI 1679749626

Payments from drug & device makers

$2,050in general payments, 2019–2025

Across 112 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$598
  • Travere Therapeutics, Inc.$333
  • Novartis$249
  • Mallinckrodt Hospital Products Inc.$167
  • Calliditas Therapeutics US Inc.$141
  • Bayer$109
  • plus $453 from 10 others

What the payments were for

  • Food & beverage$2,03699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,050 in reported general payments places this provider in the 60th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$264,027
Medicare patients
311
Services billed
2,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TarpeyoBudesonide18$302,004
FarxigaDapagliflozin Propanediol132$122,961
JardianceEmpagliflozin51$59,622
LokelmaSodium Zirconium Cyclosilicate42$45,259
Bumetanide105$4,390
SpsSodium Polystyrene Sulfon/Sorb11$2,586
Calcium Acetate22$2,494
Valsartan44$1,695
Nifedipine ErNifedipine34$1,389
Irbesartan37$1,074
Spironolactone64$787
Metoprolol Succinate39$754
Losartan Potassium67$734
Calcitriol33$622
Allopurinol64$620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Calliditas Therapeutics US Inc.Tarpeyo$141$302,00418 claims
AstraZenecaFarxiga, Lokelma$598$168,221174 claims
Boehringer IngelheimJardiance$43$59,62251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 325 nephrology providers in Michigan.

Other nephrology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →